Description

Insulin Glargine is a recombinant insulin analog engineered with amino acid modifications that shift its isoelectric point to produce microcrystalline precipitates under physiological pH, ensuring gradual absorption and a flat, peakless action profile lasting around 24 hours. Widely used for basal insulin delivery in Type 1 and Type 2 diabetes, it supports steady glycemic control. Its stability and predictability also make it a valuable tool for research into insulin receptor signaling, glucose uptake, and metabolic studies. Produced with high purity (?95%) and GMP grade to ensure consistency.

Insulin Glargine Product Specifications

Insulin Glargine Mechanism of Action & Research Applications

Insulin Glargine binds the insulin receptor, activating the tyrosine kinase pathway to promote glucose uptake in liver, muscle, and adipose tissue, while reducing hepatic glucose output. The modified molecule forms microcrystals post-injection, releasing insulin slowly to mimic physiological basal insulin:

• Glucose metabolism studies including insulin receptor signaling

• Basal-bolus dynamics in diabetes model systems

• Pharmacokinetics of basal insulin analogs

• Comparative studies against regular insulin or other analogs in metabolic assays

Insulin Glargine Side Effects (For Research Context Only)

In controlled experimental models, Insulin Glargine may cause:

• Hypoglycemia when dosing is excessive or not paired with glucose monitoring

• Local tissue effects such as mild erythema or injection-site irritation

• Weight gain in long-term systemic use, useful in adipose deposition studies

Disclaimer

This product is intended strictly for laboratory research use and is not approved for any diagnostic, therapeutic, or clinical application.